Ultrasound-guided fine-needle aspiration cytology of lesions in the head and neck performed without local anaesthesia – An analysis of pain perception

Ultrasound
2018, Vol. 26(4) 222–228
© The Author(s) 2018
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1742271X18780137
journals.sagepub.com/home/ult

Nicholas Drage¹, Christopher Greenall² and Damian JJ Farnell³

Abstract

Introduction: Ultrasound-guided fine-needle aspiration cytology is commonly carried out in the head and neck. The aim was to examine the amount of pain experienced by patients undergoing this procedure carried out without the use of local anaesthetic.

Methods: A questionnaire was given to 109 consecutive patients undergoing ultrasound-guided fine-needle aspiration cytology containing a visual analogue scale. Patients were asked to mark with a vertical line on the 100 mm horizontal scale amount of pain they experienced during the biopsy. The pain was subsequently categorised as 'no pain', 'mild pain', 'moderate pain' or 'severe pain' based on previous pain studies.

Results: Hundred patients completed the visual analogue scale section of the questionnaire satisfactorily. Twenty-one patients experienced no pain, 62 experienced mild pain and 17 experienced moderate pain. No patients experienced severe pain. Further analysis showed that females had significantly higher visual analogue scale scores (Mann–Whitney test: $U = 925.5$, $z = 2.211$, $P = 0.027$). Patients who were aware that they were going to have a biopsy had significantly lower visual analogue scale scores than those who were not aware (Mann–Whitney test: $U = 859.5$, $z = 2.263$, $P = 0.024$).

Conclusions: Ultrasound-guided fine-needle aspiration cytology is generally a well-tolerated procedure with pain scores being higher in females. It is advised that patients are told by the referring clinician the need for biopsy as this reduces the amount of pain experienced.

Keywords

Biopsy, ultrasound, pain

Date received: 13 March 2018; accepted: 26 April 2018

Introduction

Ultrasound-guided fine-needle aspiration cytology (UGFNAC) is a commonly performed procedure in the radiological assessment of patients with a head and neck swelling. Indeed, ultrasound-guided assessment and biopsy of neck lumps are now recommended in the most recent NICE guidance on the management of upper aerodigestive tract cancer.¹ It is not unreasonable to assume, therefore, that there will be a greater demand for ultrasound-guided fine-needle aspiration neck biopsy. UGFNAC is a quick and relatively easy

¹University Dental Hospital, Cardiff and Vale University Health Board, UK

²Abertawe Bro Morgannwg University Health Board, Swansea and Cwm Taf University Health Board, UK

³School of Dentistry, Cardiff University, UK

Corresponding author:

Nicholas Drage, Cardiff and Vale University Health Board, Cardiff CF14 4XY, UK.
Email: nicholas.drage@wales.nhs.uk

technique to perform in an outpatient department. The technique has a high accuracy for both lymph node and salivary gland lesions.²⁻⁴

Generally, local anaesthesia is not used when we carry out UGFNAC, as in our clinical experience most patients tolerate the procedure well. The procedure is fully explained to the patient beforehand, and the patients' anxieties allayed as much as possible.

The data arose from an audit/service review comprising a patient satisfaction questionnaire given to patients attending the department. Part of the purpose of the audit was to evaluate the pain experienced by adult patients undergoing UGFNAC of lesions in the head and neck.

Methods

This work formed part of a registered audit/service review. One hundred and nine consecutive patients were given a questionnaire to complete after undergoing fine-needle aspiration of extra-thyroid lesion/s in the head and neck. The questionnaire covered the service provided by the department but also included a question on the amount of pain the patient experienced during the biopsy.

Patients underwent high-resolution ultrasound of the head and neck using a Toshiba Aplio 500 ultrasound machine (Toshiba Medical Systems, Otawara-Shi, Japan) using either a 18 MHz or a 14 MHz ultrasound probe. If biopsy was required, the procedure was explained to the patient and verbal consent obtained.

The biopsy was carried out using an aseptic technique without local anaesthetic. The needle is inserted adjacent to the centre of the short axis of the probe. Once the lesion was penetrated, the needle was gently rotated and moved backwards and forwards to obtain the sample. A capillary method was used with no suction applied to the needle aspiration.

In most cases, the sample was obtained using a 21G (green) needle although occasionally other needle types were used; 23G (blue needle) or a 22G spinal needle for deeper lesions. The biopsies were performed by a Consultant Dental and Maxillofacial Radiologist and an experienced trainee in Dental and Maxillofacial Radiology.

The age, gender, biopsy site, needle type, operator and number of passes made were recorded on the back of the questionnaire. In some cases, the patient was aware that the biopsy was going to be performed prior to the appointment and this was also recorded. It was also recorded whether an information sheet on UGFNAC had been given to the patient prior to the appointment.

The patient was then given the questionnaire to complete in the waiting room anonymously and without

3. On the following scale mark with a vertical line the amount of pain you experienced during the biopsy

No pain ————— Pain could not be worse

Figure 1. The visual analogue scale question that the patients were asked to answer.

coercion from the radiologist performing the procedure. Once completed it was handed back to the clinic coordinator. The questionnaire included a visual analogue scale (VAS) (Figure 1). The patient was asked to mark with a vertical line on a 100 mm horizontal scale the amount of pain they experienced during the biopsy. The ends of the scale were marked 'no pain' and 'pain cannot be worse'. There were no intermediary markings on the scale.

Once returned, the VAS scores were measured to the nearest 1 mm with a ruler. The score was then categorised into four groups: No pain (VAS score 0–4 mm), mild pain (VAS score 5–44 mm), moderate pain (VAS score 45–74 mm) and severe pain (VAS score 75–100 mm), as suggested by Jensen et al.⁵

Statistical tests

Descriptive statistics and graphical methods were used to explore the data initially. VAS scores were found to be heavily right-skewed, and so medians, as well as means, are quoted here. 95% confidence intervals (95% CI) of the mean, standard deviations, and interquartile ranges are also quoted. The right-skew of the data could not be corrected via application of logarithms, and so non-parametric tests were used here to test for differences between groups, namely, the Mann–Whitney test for all two-group comparisons and Kruskal–Wallis test (non-parametric one-way ANOVA) for comparisons of three or more groups. Due to the heavy right-skew of the VAS data, the relationship between VAS scores for males and females independently was explored using Spearman's rank-correlation coefficient (ρ) and also by gamma regression. Gamma regression is the preferred method when data is right-skewed, and inspection of residuals showed that they followed a gamma distribution, as required. Median regression was also carried out (results not quoted here), and the results were found to be broadly similar to results of gamma regression. All inferential statistical tests were carried out using SPSS V23, and gamma regression was carried out using STATA V13.

Results

Of the 109 questionnaires given to the patients, 100 had the VAS scale marked giving a response rate of 92%.

The subject and biopsy characteristics are given in Table 1. The mean age of the subjects was 58.17 years, and the youngest subject was 18 years old, and the oldest subject was 96 years old. There were roughly equal numbers of males and females. In the vast majority of cases (97%), the information sheet was not given to the patient. Thirty-eight percent of subjects were aware about the biopsy taking place, and the procedure was carried out by two operators. In the vast majority of cases (97%), a green needle gauge was used, and the median and modal average number of passes was equal to 2. The site for the procedure was mainly in the lymph node region (64%), salivary gland region (23%), both lymph node and salivary gland regions (4%), with 'other areas' (i.e. cheek, lesion in supraclavicular fossa, lesion in occipital region) accounting for the remaining 9% of cases.

The VAS scores grouped together into the pain categories is shown in Table 2. VAS scores as a function of various groupings are shown in Table 3. This shows that the females had significantly higher VAS scores (Mann–Whitney test: $U = 925.5$, $z = 2.211$, $P = 0.027$) than men, where the difference in mean VAS scores between males and females was 9.414 (95% CI: 1.707 to 17.121). Furthermore, those subjects that were aware about the biopsy had significantly lower VAS scores than those subjects who were not aware (Mann–Whitney test: $U = 859.5$, $z = 2.263$, $P = 0.024$), where the difference in mean VAS scores between 'aware' and 'not aware' was 7.640 (95% CI: -0.373 to 15.654). Although there was some evidence that VAS scores increased with increasing number of passes up to the three passes, no significant differences occurred (Kruskal–Wallis test: $\chi^2 = 3.812$, $\text{DOF} = 3$, $P = 0.283$). Furthermore, four or more passes demonstrated anomalous results (e.g. mean VAS score = 16). Finally, there was no significant differences in VAS scores by site (either lymph node or salivary gland: Mann–Whitney test: $U = 612$, $z = 1.194$, $P = 0.232$) or by operator: Mann–Whitney test: $U = 842$, $z = 0.57$, $P = 0.569$). Sample sizes were too low in some groups for the other variables (e.g. needle gauge) to allow reliable quantitative comparison of VAS scores for these variables.

The relationship between VAS and age (in years) was investigated using scatter plots, as shown in Figure 2. 'Lines of best fit' shown in these figures were formed using gamma regression, which is appropriate for right-skewed data. We see that VAS scores for males reduce strongly with age. It was found that the line of best fit of VAS scores scaled with age (in years) followed the expression: $\text{VAS} = 60.9244 \times \exp\{-0.0229 \times \text{age}\}$. This result indicates a statistically significant 2.26% 'compound' reduction ($z = -2.92$ and $P = 0.003$) in VAS each year for males only, for

Table 1. Subject and biopsy characteristics.

	Mean	Median	Minimum	Maximum
Age (years)	58.17	60	18	96
Gender	Males ($n = 47$)	Females ($n = 53$)		
Information sheet given to patient	Yes ($n = 3$)	No ($n = 97$)		
Aware about biopsy taking place	Yes ($n = 38$)	No ($n = 62$)		
Operator	Consultant ($n = 65$)	Trainee ($n = 28$)	Both ($n = 7$)	
Needle gauge used for biopsy	21G, green ($n = 97$)	23G, blue ($n = 1$)	Both 21G and 23G ($n = 1$)	Spinal needle (22G) ($n = 1$)
Number of passes made with the needle into lesion	1 pass ($n = 28$)	2 passes ($n = 50$)	2 passes ($n = 13$)	4 or more passes ($n = 9$)
Site	Lymph nodes (LN) ($n = 64$)	Salivary gland (SG) ($n = 23$)	Both LN and SG ($n = 4$)	Other ($n = 9$)

example, an initial value of $VAS=30.0$ reduces to $VAS=30.0 \times \exp\{-0.0229 \times 50\}=9.5$ over 50 years. We see from Figure 2 that VAS scores for females reduce slightly with age. It was found that the line of best fit of VAS scores scaled with age (in years) followed the expression: $32.7828 \times \exp\{-0.0030 \times \text{age}\}$. This result indicates a 0.3% ‘compound’ reduction ($z=-0.60$ and $P=0.545$) in VAS each year for females only, for example, an initial value of $VAS=30.0$

reduces to $VAS=30.0 \times \exp\{-0.0030 \times 50\}=25.8$ over 50 years. Finally, results for Spearman’s correlation coefficient (ρ) of VAS with age agree with all of these results presented above, that is, ρ for males $=-0.364$ ($P=0.012$) and ρ for females $=-0.021$ ($P=0.825$). Thus, males again demonstrate a negative correlation of VAS scores with age that is significant, whereas females demonstrate (at best) a very weak negative correlation of VAS scores with age.

Discussion

VAS is a well-established technique for the assessment of pain following UGFNAC.^{6–9} Our results demonstrated that most patients experienced either mild pain ($n=62$) or no pain ($n=21$). Seventeen patients experienced moderate pain, and none experienced severe pain. The cut-off points of the categories were those suggested by Jensen et al.⁵ The pain categories are based on the distribution of pain following surgery,¹⁰ but they have subsequently been used to evaluate pain following biopsy in the head and neck.⁹

VAS has been shown to be a reliable and valid method of assessing acute pain.¹¹ VAS is quick and simple to carry out and has been used in several studies

Table 2. VAS scores grouped into pain categories.

VAS score	Pain category	Frequency
0–4 mm	No pain	21
5–44 mm	Mild pain	62
45–74 mm	Moderate pain	17
75–100 mm	Severe pain	0
Total		100

VAS: visual analogue scale.

Table 3. VAS scores for various groupings.

	Mean (95% CI)	Sample standard deviation	Median	IQR
Males	17.51 (12.48–22.54)	17.141	12	25
Females	26.92 (21.09–32.76)	21.169	22	32
Aware = yes	17.76 (11.22–24.31)	19.917	10.5	28
Aware = no	25.40 (20.47–30.33)	19.406	22	30
1 pass	18.29 (11.84–24.74)	16.635	13	28
2 passes	23.53 (17.74–29.30)	20.322	19.5	35
3 passes	32.15 (19.53–44.78)	20.888	31	37
4 or more passes	16.00 (<0–33.06)	22.192	5	14
Lymph nodes	24.67 (19.61–29.74)	20.276	19	33
Salivary glands	19.30 (11.18–27.43)	18.792	13	24
Operator (consultant)	22.05 (17.26–26.84)	19.335	18	32
Operator (trainee)	20.11 (12.85–27.37)	18.719	16	26
All subjects	22.50 (18.56–26.44)	19.854	18	34

CI: confidence interval; IQR : interquartile range; VAS: visual analogue scale.

Figure 2. Results of gamma regression of visual analogue scale as a function of age for males and females separately. VAS: visual analogue score.

assessing pain following fine-needle aspiration biopsy of lesions in the head and neck.^{6,8,12} Other established methods of pain assessment include the Numeric Rating Scale (NRS) and the Verbal Rating Scale (VRS), both of which can also be carried out graphically. The NRS is quick and easy to score but has been shown to have poor reproducibility.¹³ VAS is more sensitive than VRS because a larger change is required before it becomes evident on the scale.¹⁴ Overall VAS seems to be the most statistically robust method of assessing pain.¹⁴

We found that women had a significantly higher VAS score than males, a finding also reported following biopsy of thyroid nodules.⁹ There is strong evidence of an increased sensitivity to pain and pain threshold in women.^{15,16} Although the reasons for the differences in pain perception between the sexes is unknown, it is thought to be multifactorial with genotype and endogenous opioid functioning playing a major role.¹⁷ Sex hormones are also thought to play an important role in pain perception.¹⁷ However, it should be noted that other studies have found no differences in pain perception between the genders during biopsy.^{7,18}

Age differences in pain perception are not well understood,¹⁹ with some studies reporting an increase in experimental pain in older adults and others

reporting the opposite findings.^{20,21} However, several studies have reported no differences in pain scores and age.^{6,9,18,22} We found that VAS scores for males reduced markedly with age and the VAS scores for females reducing slightly with age. Overall our findings support the findings of a recent study that reported higher VAS scores in younger patients.²³

Anxiety may also play a role in pain perception.²⁴ This may partially explain why those patients who knew that they were going to have a biopsy generally reported lower pain scores. Presumably, these patients had time to assimilate the information and were, therefore, less anxious about the procedure. As far as we are aware, this finding has not been reported before in relation to UGFNAC in the head and neck. The sample size was too small to examine whether the information sheet would be helpful, but it seems sensible to provide one whenever possible to allay patients' concerns. One of the action points following the audit was to produce a patient information video on what to expect when having a biopsy carried out.

In our audit/service review, we found no differences in VAS scores between the two operators. Although one of the operators was a trainee, they were experienced in performing the procedure. A previous study also showed no differences in pain scores between radiologists with different levels of experience.²²

A study on thyroid FNAC found that pain scores were related to the number of passes.²³ Our results showed that there was some evidence of an increase in pain scores with the number of passes, but this was not significant. Furthermore, the pain scores for three passes were generally higher than for four passes indicating larger sample sizes are required to look at this effect.

When we compared the pain scores from biopsies of the salivary glands with those from lymph nodes we found no significant differences. In a recent study by Lo et al., they found that pain scores from lymph nodes were significantly higher than thyroid nodules. The authors were not clear why there was a difference but proposed this may partly be due to the distribution of sensory nerve endings in the neck.²⁵

We did not record the depth of the lesion in our audit data set, but it is known that there is an association between lesion depth in the thyroid and increased VAS score.¹⁸ Thyroid biopsy was not included in this audit/service review as these procedures are performed by a different team.

We do not routinely use any topical or injected local anaesthetic during UGFNAC. There are conflicting results on whether topical local anaesthetic is useful.^{6,9} In addition, the use of topical anaesthetic potentially increases the appointment time and adds to the overall cost of the procedure. Alternatively, local anaesthetic can be injected prior to UGFNAC.

Despite some papers advocating local anaesthetic injection before ultrasound-guided biopsy in other sites such as prostate,²⁶ pain scores can be higher using this technique in the head and neck.¹² For this reason, it is not recommended to use this technique if there is going to be only a single pass of the biopsy needle.

In the United Kingdom, recently published National Institute for Clinical Excellence guidance in the management of patients with upper aerodigestive tract cancer recommends the use of ultrasound-guided biopsy as part of the assessment of a neck swelling.¹ While the presentation of a 'neck lump' encompasses a range of benign and malignant diseases, differentiating between the two may only be possible with UGFNAC. Certainly, the role of ultrasound in the diagnostic work-up of these patients will increase. While different models of access to this type of service exist throughout the UK, our work highlights some useful findings which may be taken into consideration when designing a patient-centred neck lump service.

Conclusions

- FNAC is generally well-tolerated procedure with most patients experiencing either mild pain or no pain during the procedure. No patients experienced severe pain.
- There was no difference in VAS scores between lymph node biopsy and salivary gland biopsy.
- VAS scores were significantly higher in females than males.
- VAS scores for males reduced markedly with age.
- VAS scores were higher in those patients who were not aware they were going to have a biopsy before the appointment. It is advised therefore that patients are told by the referring clinician the need for biopsy and if possible provide the patient with information on the procedure prior to the appointment.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics approval

Reviewed by the Clinical governance/quality and safety audit group at Cardiff University Dental hospital and presented at

local clinical governance meeting in the University Dental hospital. R&D approval was not required.

Guarantor

ND.

Contributors

ND and CG undertook the study design, literature search, clinical studies, manuscript preparation and editing. DF undertook the statistical analysis, as well as manuscript preparation and editing.

References

1. National Collaborating Centre for Cancer (UK). *Cancer of the Upper Aerodigestive Tract: Assessment and Management in People Aged 16 and Over*. London: National Institute for Health and Care Excellence (UK); 2016 Feb. (NICE Guideline, No. 36.) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK344100/>.
2. Gudmundsson JK, Ajan A and Abtahi J. The accuracy of fine-needle aspiration cytology for diagnosis of parotid gland masses: a clinicopathological study of 114 patients. *J Appl Oral Sci* 2016; 24: 561–567.
3. Goret CC, Goret NE, Ozdemir ZT, et al. Diagnostic value of fine needle aspiration biopsy in non-thyroidal head and neck lesions: a retrospective study of 866 aspiration materials. *Int J Clin Exp Pathol* 2015; 8: 8709–8716.
4. Iacob A, Zazgyva A, Ormenisan A, et al. Effectiveness of fine-needle aspiration cytology in the diagnosis of lateral cervical nonthyroid tumors. *Medicine* 2016; 95: e4448.
5. Jensen MP, Chen C and Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. *J Pain* 2003; 4: 407–414.
6. Demirci H, Erdamar H, Karakoc A, et al. Thyroid fine needle aspiration biopsy: is topical local anaesthesia beneficial? *Int J Clin Pract* 2010; 64: 25–28.
7. Yuce I, Turkeli M, Eren S, et al. How can we reduce the pain associated with FNA biopsy? Comparison of parallel and perpendicular method. *Jpn J Radiol* 2016; 34: 503–507.
8. Brennan PA, Mackenzie N, Oeppen RS, et al. Prospective randomized clinical trial of the effect of needle size on pain, sample adequacy and accuracy in head and neck fine-needle aspiration cytology. *Head Neck* 2007; 29: 919–922.
9. Gursoy A, Ertugrul DT, Sahin M, et al. The analgesic efficacy of lidocaine/prilocaine (EMLA) cream during fine-needle aspiration biopsy of thyroid nodules. *Clin Endocrinol (Oxf)* 2007; 66: 691–694.
10. Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis Care Res (Hoboken)* 2011; 63(Suppl. 11): S240–S252.
11. Gallagher EJ, Bijur PE, Latimer C, et al. Reliability and validity of a visual analog scale for acute abdominal pain in the ED. *Am J Emerg Med* 2002; 20: 287–290.
12. Kim DW, Rho MH and Kim KN. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules: is it necessary to use local anesthesia for the application of one needle puncture? *Korean J Radiol* 2009; 10: 441–446.

13. Van Tubergen A, Debats I, Ryser L, et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. *Arthritis Rheum* 2002; 47: 242–248.
14. Williamson A and Hoggart B. Pain: a review of three commonly used pain rating scales. *J Clin Nurs* 2005; 14: 798–804.
15. Pieretti S, Di Giannuario A, Di Giovannandrea R, et al. Gender differences in pain and its relief. *Ann Ist Super Sanita* 2016; 52: 184–189.
16. Maurer AJ, Lissounov A, Knezevic I, et al. Pain and sex hormones: a review of current understanding. *Pain Manag* 2016; 6: 285–296.
17. Bartley EJ and Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. *Br J Anaesth* 2013; 111: 52–58.
18. Toman H, Ozkul F, Erbag G, et al. Effects of fine-needle aspiration biopsy (FNAC) nodule depth on pain score. *Ir J Med Sci* 2016; 185: 673–676.
19. Wandner LD, Scipio CD, Hirsh AT, et al. The perception of pain in others: how gender, race, and age influence pain expectations. *J Pain* 2012; 13: 220–227.
20. Lautenbacher S, Kunz M, Strate P, et al. Age effects on pain thresholds, temporal summation and spatial summation of heat and pressure pain. *Pain* 2005; 115: 410–418.
21. Rittger H, Rieber J, Breithardt OA, et al. Influence of age on pain perception in acute myocardial ischemia: a possible cause for delayed treatment in elderly patients. *Int J Cardiol* 2011; 149: 63–67.
22. Lee YJ, Kim DW and Jung SJ. Comparison of sample adequacy, pain-scale ratings, and complications associated with ultrasound-guided fine-needle aspiration of thyroid nodules between two radiologists with different levels of experience. *Endocrine* 2013; 44: 696–701.
23. Leboulleux S, Borget I, Labro S, et al. Frequency and intensity of pain related to thyroid nodule fine needle aspiration cytology. *Thyroid* 2013; 23: 1113–1118.
24. Craig AD. Pain mechanisms: labeled lines versus convergence in central processing. *Annu Rev Neurosci* 2003; 26: 1–30.
25. Lo WC, Cheng PW, Wang CT, et al. Pain levels associated with ultrasound-guided fine-needle aspiration biopsy for neck masses. *Head Neck* 2014; 36: 252–256.
26. Leibovici D, Zisman A, Siegel YI, et al. Local anesthesia for prostate biopsy by periprostatic lidocaine injection: a double-blind placebo controlled study. *J Urol* 2002; 167(2 Pt 1): 563–565.